![]() |
Laure-Marie Dardaud
Auteur
Céline Bris 1
Auteur
Valérie Desquiret-Dumas 2
Auteur
Blandine Boisselier 3
Auteur
Emeline Tabouret 4, 5
Auteur IdHAL : emeline-tabouret ORCID : https://orcid.org/0000-0002-4031-2178
Karima Mokhtari 6
Auteur
Dominique Figarella-Branger 4, 7, 8
Auteur IdHAL : dominique-figarella-branger
Audrey Rousseau 9
Auteur
Vincent Procaccio 2, 10
Auteur
Glioblastoma (GB) is the most common and most aggressive form of diffuse glioma, with a median overall survival of 15 months after standard of care.1 Young GB patients (<40 years old) may carry isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations or, in rare instances, harbor H3F3A or HIST1H3B mutations. Other cases are wild-type for those genes and harbor gain of chromosome (chr) 7, loss of chr 10, and epidermal growth factor receptor (EGFR) amplification (amp). IDH1/2 mutations are associated with longer survival (24 mo), whereas...
UNIV-ANGERS | UNAM | CRCINA | UNIV-NANTES | INP | UNIV-AMU | INP-GLIOME | CNRS | MITOVASC | CRCINA-GLIAD